A Novel Noninvasive Thermoregulatory Device for Postural Tachycardia Syndrome
- Conditions
- Postural Tachycardia Syndrome
- Interventions
- Device: Embr Device
- Registration Number
- NCT04943276
- Lead Sponsor
- Stanford University
- Brief Summary
The investigators hope to learn the feasibility and preliminary efficacy of the Embr device for improving thermal comfort in individuals with POTS and impaired thermoregulation. Feasibility will be assessed via usage of the Embr device and participant feedback. Preliminary efficacy measures will include temperature-related symptoms and temperature- related quality of life in individuals with POTS and impaired thermoregulation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
- Diagnosis of POTS
- Participant self-report of heat or cold intolerance
- Willingness to wear the Embr device for 3 weeks, charging the device daily, and
- Have a working smartphone (iPhone 6 or greater; or Android 8.0 or greater
- Comfortable downloading and using the companion app on their phone
- Able to provide informed written consent
- Able to complete written questionnaires
- Prior or current use of the study device
- Hypohidrosis, hyperhidrosis, or anhidrosis, as determined by sudomotor testing; peripheral neuropathy; perimenopausal, menopausal, postmenopausal state; temperature intolerance due to other medical disorders (i.e. malignancy, systemic autoimmune disease)
- Medications known to affect sweat function
- Non-English speaking
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Embr Watch Embr Device Participants will receive the device and a technical onboarding video 3 days prior to study start to allow time for familiarization with the device and troubleshooting any technical questions or problems prior to study start. The study will consist of baseline measurements prior to using the Embr device and weekly outcome assessments at Week 1, 2, 3, and 4
- Primary Outcome Measures
Name Time Method Change from baseline in Pittsburg Sleep Quality Index (PSQI) at study endpoint Baseline and end of study ( 4 weeks) PSQI score ranges in value from 0 to 21. A score of 0 indicates no sleep difficulties, while more-severe sleep difficulties correspond to higher values.
Change from baseline in Compass-31 survey at study endpoint Baseline and end of study ( 4 weeks) Compass 31 score ranges in value from 0 to 100. A score of 0 indicates no autonomic symptoms, while more-severe autonomic symptoms correspond to higher values.
Change from baseline in Insomnia Severity Scale Index (ISI) at study endpoint Baseline and end of study ( 4 weeks) Scale range is 0-28, with 0 indicating absence of insomnia and 28 indicating severe insomnia.
Temperature Quality of life Questionnaire Week 1,2,3,4 Temperature related daily interference scale Week 1,2,3,4 Scale range is 0-100, with a higher score indicating more problems with thermoregulation.
OCEAN Temperature Related Psychogenic Questionnaire Week 1,2,3,4
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Stanford Neuroscience Health Center
🇺🇸Stanford, California, United States